Imprimis Pharmaceuticals' Go Dropless? Cataract Surgery Formulations to be Featured in Two Sessions at the 2014 American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium - Applied Clin

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Imprimis Pharmaceuticals' Go Dropless? Cataract Surgery Formulations to be Featured in Two Sessions at the 2014 American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium - Imprimis' proprietary ophthalmic compounded formulations now available by prescription in 32 states and territories -


Imprimis Pharmaceuticals' Go Dropless™ Cataract Surgery Formulations to be Featured in Two Sessions at the 2014 American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium

- Imprimis' proprietary ophthalmic compounded formulations now available by prescription in 32 states and territories -

PR Newswire

SAN DIEGO, July 24, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations,  announced today that two Key Opinion Leader (KOL) presentations that describe the benefits of dropless cataract surgery formulations will be delivered at the upcoming American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium in Deer Valley, Utah from July 24 – 27, 2014.  

The American-European Congress of Ophthalmic Surgery is a unique collaboration of physicians, ophthalmic industry executives, select venture capitalists and technology entrepreneurs. The Society meets three times each year - in the US and Europe - to evaluate new developments in technology, surgical technique, clinical studies and progressive patient care. Its mission is to advance vision care and improve patients' quality of life through Innovation, Education and Advocacy.

Imprimis continues its Go Dropless™ campaign (http://dropless.com/), which has been created to inform ophthalmologists about dropless ophthalmic surgery opportunities and the unique injectable compounded drug formulations the company has developed in conjunction with physicians and pharmacists. Details of the AECOS presentations include:

  • Friday, July 25, 20149:20 a.m.9:30 a.m. MDT "Branded vs. Generic Options: What's Happening with Drop Prices? How Does It Impact the Premium Practice/Procedure?," Dr. Carlos Buznego
  • Sunday, July 27, 2014 - 7:08 a.m.7:16 a.m. MDT "Use of Intraocular Meds During Cataract Surgery with the Goal of Reducing or Eliminating Post-Op Drops," Dr. William Trattler

Imprimis' proprietary patent-pending ophthalmic compounded formulations are now available with a physician's prescription in 32 states and territories while the Company continues its Go Dropless™ campaign (http://GoDropless.com/). Currently two compounded antibiotic and steroid formulations are available in single, injectable, intraocular doses administered during cataract surgery. The preservative-free formulations generally contain 15 mg triamcinolone plus 1 mg moxifloxacin per ml and can also include vancomycin and the relative strengths of the active ingredients can be tailored to individual patients.  Advantages include reduction of compliance concerns, reduction of staff and chair time spent on instructions and follow-up with post-operative surgical patients, as well as calls from pharmacists. Two recent studies both found the use of these formulations to be positive in overall patient compliance, cost, and general experience.1-2 

Furthermore, the company recently shared results of a survey of leading national cataract surgeons that showed 20 out of the 21 physicians surveyed expressed favorable opinions to the concept of Imprimis' single intraocular injection administered at the conclusion of cataract surgery.  These surgeons' perspectives examine the benefits of dropless cataract surgery for both doctors and patients. Specifically, the surgeons highlighted attributes related to convenience and compliance. To watch the complete video interviews, interested parties can go to www.GoDropless.com/why-go-dropless.

ABOUT IMPRIMIS PHARMACEUTICALS
San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients at accessible prices. Imprimis is pioneering a new commercial pathway using compounding pharmacies for the formulation and distribution of its proprietary drug therapies which include formulations in ophthalmology, wound management and urology. For more information, please visit www.imprimispharma.com or www.GoDropless.com.

SAFE HARBOR
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its compounded formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; risks related to its compounding pharmacy operations; including its ability to maintain compliance with applicable state and federal laws and regulations; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

1 Liegner J. Better surgery through chemicals. Presented at the American Society for Cataract and Refractive Surgeons Annual Meeting. April 25-29. Boston, MA.

2 Galloway MS. Intravitreal placement of antibiotic/steroid as a substitute for post-operative drops following cataract surgery. Presented at the American Society for Cataract and Refractive Surgeons Annual Meeting. April 25-29. Boston, MA.

MEDIA CONTACT:  Jen Carroll
jcarroll@imprimispharma.com
858.704.4587

SOURCE Imprimis Pharmaceuticals

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here